Remicade has been found to make the COVID-19 vaccine less effective.
A new study published on March 29 has shown that frequent infusions of infliximab (Remicade) have been shown to make first vaccine doses in both Pfizer and AstraZeneca less effective.
The researchers came to the conclusion that patients who were receiving regular infliximab injections as an antibody treatment for several chronic inflammatory illnesses did not produce enough antibodies to offer protection against COVID-19, after the first vaccine dose.
Remicade is usually used for treating several autoimmune disorders, such as ankylosing spondylitis, psoriatic arthritis, Crohn’s disease, rheumatoid arthritis, ulcerative colitis, and plaque psoriasis.
